D0112-005 / Easton Biopharma - LARVOL DELTA

Examination of in vitro and in vivo antitumor activity of PARP1 selective inhibitor D0112-005. (ASCO 2024) - "In rat 28 days repeat dose study, D0112-005 100mg/kg had less changes on hematologic parameters compared with Olaparib. D0112-005 potently and selectively inhibits PARP1 resulting in excellent anti-tumor activity in vivo and in vitro, which also good safety profile in the repeated toxicity study in rats and dogs."

Preclinical • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • Thrombocytopenia • BRCA • BRCA1 • HRD • PARP2 • PARP3